Verified factor-similar pair

JHSC vs SMMD

These two ETFs meet the same FF6 US comparison criteria: US-listed equity ETFs, the same USD model basis, at least one material non-market factor, and 100% overlap in statistically significant material factor exposure.

SMB
Similarity score
88
Verified similar

The score combines exposure-level distance, factor-vector shape, market-beta closeness, and a small backtested relative-Sharpe term.

Quick Read

  • SMMD has the higher backtested relative Sharpe (0.773 vs 0.661).
  • SMMD has the lower published fee (0.23% vs 0.46%).
  • JHSC is cheaper on dividend valuation (110 vs 135, where 100 is each fund's historical median).
  • SMMD has the stronger regression fit (adjusted R-squared 0.975 vs 0.964).

These are screening signals, not a complete review of portfolio construction, turnover, taxes, or trading quality.

JHSC

John Hancock Multifactor Small Cap ETF
SMB
Adj. R2
0.964
Rel. Sharpe
0.661
Mkt beta
0.99
AUM
US$703M
MER
0.46%
Valuation
110

SMMD

iShares Russell 2500 ETF
SMB
Adj. R2
0.975
Rel. Sharpe
0.773
Mkt beta
1.03
AUM
US$2.9B
MER
0.23%
Valuation
135

Factor Exposure Match

Blue bars compare raw factor beta magnitude. Green bars compare absolute t-stat strength. Dim bars indicate the t-stat is below 1.96.

SMB
JHSC
+0.65
|t|
+13.9
SMMD
+0.61
|t|
+16.0
diff +0.04
HML
JHSC
+0.21
|t|
+5.0
SMMD
+0.13
|t|
+4.0
diff +0.07
RMW
JHSC
+0.11
|t|
+2.3
SMMD
-0.08
|t|
-1.9
diff +0.19
CMA
JHSC
-0.02
|t|
-0.3
SMMD
-0.00
|t|
-0.0
diff -0.02
UMD
JHSC
+0.04
|t|
+1.2
SMMD
+0.03
|t|
+1.1
diff +0.01

Why This Pair Matches

Exposure level
86
Exposure shape
98
Mkt beta diff
0.04
Rel. Sharpe diff
0.111

This comparison focuses on measured factor exposure. It does not compare holdings methodology, turnover, tax handling, or issuer process. Backtested relative Sharpe is a secondary signal rather than a stand-alone forecast. See methodology.

JHSC fund page SMMD fund page US ETF Leaders US Universe
Important context

VerifiedBeta publishes educational ETF research, not personalized investment advice, portfolio management, or security recommendations. Funds that screen well here can still be unsuitable for your objectives, taxes, liquidity needs, or constraints. Review fund documents, methodology assumptions, and your own circumstances before acting. See the full disclaimer.